Video
Dr. Bonomi Discusses PD-L1 as a Biomarker in NSCLC
Author(s):
In Partnership With:
Philip D. Bonomi, MD, The Alice Pirie Wirtz Professor of Medical Oncology, Rush Medical College, medical oncologist, Rush University Medical Center, discusses PD-L1 as a biomarker in non-small cell lung cancer.
Philip D. Bonomi, MD, The Alice Pirie Wirtz Professor of Medical Oncology, Rush Medical College, medical oncologist, Rush University Medical Center, discusses PD-L1 as a biomarker in non—small cell lung cancer (NSCLC).
Although PD-L1 is not a perfect biomarker, it remains a player in the immunotherapy arena, says Bonomi.
If regimens like combining immunotherapy and chemotherapy demonstrate good results, there may not even be a need for biomarkers, Bonomi adds.
Related Videos
Related Content
